Welcome to our dedicated page for ADC Therapeutics SA SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics SA received an amended Schedule 13G showing that investment entities affiliated with Prosight report beneficial ownership of 8,477,338 common shares, representing 6.8% of the company’s outstanding stock. All of these shares are held with shared voting and shared dispositive power.
The ownership is spread across Prosight-managed vehicles, including Prosight Fund and Prosight Plus Fund, which directly hold common shares, and certain managed accounts. The filing is certified as a passive investment, stating the securities were not acquired to change or influence control of ADC Therapeutics.
ADC Therapeutics SA released an updated corporate presentation and furnished it as an exhibit to a current report. The presentation is attached as Exhibit 99.1 and is meant to provide investors and other stakeholders with more detail about the company and its activities. The company notes that this material is being furnished under Regulation FD, which is designed to ensure fair disclosure of information. The presentation and related information are not treated as formally filed financial statements and are not automatically incorporated into other securities law filings unless specifically referenced.
ADC Therapeutics SA reported that it has released preliminary estimates for its revenue for the quarter and year ended December 31, 2025, along with preliminary cash and cash equivalents as of that date. These figures were disclosed in a press release dated January 8, 2026, which is attached as an exhibit.
The company emphasized that these revenue and cash numbers are preliminary, unaudited and based on management’s complex judgments and estimates. Actual results for the quarter and full year 2025 are not yet finalized or reviewed by independent auditors and may differ materially from these early estimates. The information is being furnished for disclosure purposes and is not deemed filed under the securities laws unless specifically incorporated by reference.
ADC Therapeutics SA reported a routine insider equity transaction by its Chief Executive Officer and director, Ameet Mallik. On 12/06/2025, 233,146 common shares were withheld by the company at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this tax-withholding event, Mallik beneficially owns 1,319,101 common shares directly. This type of Form 4 event reflects administrative handling of equity compensation rather than an open‑market purchase or sale.
ADC Therapeutics SA reported an insider equity transaction involving its Chief Medical Officer, Mohamed Zaki. On 12/06/2025, the company withheld 41,068 common shares at a price of $3.29 per share to cover his tax withholding obligations tied to previously granted restricted share units that vested. After this automatic withholding, Zaki beneficially owns 421,820 common shares, held directly. This type of transaction reflects routine share withholding for taxes rather than an open-market sale.
ADC Therapeutics SA's Chief Accounting Officer reported a routine share transaction under Form 4. On 12/06/2025, the officer had 7,140 common shares disposed of at $3.29 per share, coded as an "F" transaction. This represents shares withheld by the company to cover tax obligations related to the vesting of previously granted restricted share units.
After this withholding event, the officer directly beneficially owns 70,757 common shares of ADC Therapeutics SA. The filing reflects administrative tax settlement activity rather than an open-market buy or sell decision.
ADC Therapeutics SA reported an insider transaction by Chief Legal Officer Peter Graham. On 12/06/2025, the company withheld 49,508 common shares at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this withholding, Graham beneficially owns 359,034 common shares directly. The filing notes that this is a routine tax withholding transaction rather than an open‑market sale, and no derivative securities transactions were reported.
ADC Therapeutics SA's Chief Financial Officer, Jose Carmona, reported a routine share withholding related to equity compensation. On 12/06/2025, the company withheld 53,236 common shares to cover his tax obligations arising from the vesting of previously granted restricted share units. The shares were valued at $3.29 per share for this tax withholding event.
After this transaction, Carmona beneficially owned 488,656 common shares, held directly. The filing is a standard Form 4 disclosure of insider equity activity rather than an open-market purchase or sale.
ADC Therapeutics SA filed Amendment No. 1 to its shelf registration statement as an exhibit-only update to include a new auditor consent from PricewaterhouseCoopers SA. The company states that this amendment does not change any part of the prospectus and consists only of the facing page, an explanatory note, Part II, signatures, the exhibit index and the new exhibit.
The company estimates total offering-related expenses of $71,341.46, including a SEC registration fee of $8,341.46, legal and accounting fees and printing costs. ADC Therapeutics will bear its own registration expenses, while any selling shareholders would be responsible for brokerage commissions or similar charges if they sell shares under the registration. The filing also restates standard Swiss-law based indemnification provisions for directors and officers and includes customary Securities Act undertakings.
ADC Therapeutics SA reported new clinical data from its ongoing LOTIS-7 Phase 1b open-label trial. This study evaluates the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma, a difficult-to-treat blood cancer. As of the November 17, 2025 cutoff date, 49 patients were considered efficacy evaluable, each with at least six months of follow-up from the start of treatment. These updated data help further characterize how this drug combination performs in heavily pretreated lymphoma patients.